• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Capricor Therapeutics Inc.

    2/7/24 3:01:16 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CAPR alert in real time by email
    SC 13G 1 p24-0662sc13g.htm CAPRICOR THERAPEUTICS, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.  )*
     

    Capricor Therapeutics, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    14070B309

    (CUSIP Number)
     

    December 31, 2023

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 6 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 14070B30913GPage 2 of 6 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Highbridge Capital Management, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    2,789,699

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    2,789,699

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,789,699

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.1%

    12

    TYPE OF REPORTING PERSON

    IA, OO

             

     

     

    CUSIP No. 14070B30913GPage 3 of 6 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Capricor Therapeutics, Inc. (the “Company”).

     

    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company’s principal executive offices are located at 10865 Road to the Cure, Suite 150, San Diego, California 92121.

     

    Item 2(a). NAME OF PERSON FILING:

     

      This statement is filed by Highbridge Capital Management, LLC (“Highbridge” or the “Reporting Person”), a Delaware limited liability company and the investment adviser to certain funds and accounts (the “Highbridge Funds”), with respect to the shares of Common Stock (as defined in Item 2(d) below) directly held by the Highbridge Funds.
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

     

    The address of the business office of Reporting Person is 277 Park Avenue, 23rd Floor,

    New York, New York 10172.

     

    Item 2(c). CITIZENSHIP:

     

      Highbridge is a Delaware limited liability company.  

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.001 per share (the “Common Stock”).

     

    Item 2(e). CUSIP NUMBER:
       
      14070B309

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act,
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
      (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,

     

     

    CUSIP No. 14070B30913GPage 4 of 6 Pages

     

      (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,
      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E),
      (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
      (g) ¨ Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
      (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act,
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J),
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:                                                                                         

     

    Item 4. OWNERSHIP:
       
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page of the Reporting Person and is incorporated herein by reference.
       
      The percentage set forth herein is calculated based upon 30,792,869 shares of Common Stock outstanding as of November 13, 2023, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, filed with the Securities and Exchange Commission on November 14, 2023.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
       
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
       
      See Item 2.  The Highbridge Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein. Highbridge Tactical Credit Master Fund, L.P., a Highbridge Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the shares of Common Stock.

     

     

    CUSIP No. 14070B30913GPage 5 of 6 Pages

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP:
       
      Not applicable.

     

    Item 10. CERTIFICATION:

     

      The Reporting Person hereby makes the following certification:
       
      By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    CUSIP No. 14070B30913GPage 6 of 6 Pages

    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    DATED:  February 7, 2024  
       
      HIGHBRIDGE CAPITAL MANAGEMENT, LLC
         
         
      By: /s/ Kirk Rule
      Name: Kirk Rule
      Title: Executive Director

     

    Get the next $CAPR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAPR

    DatePrice TargetRatingAnalyst
    6/30/2025$20.00Buy
    Alliance Global Partners
    6/26/2025$21.00Buy
    B. Riley Securities
    5/20/2025$31.00Buy
    Roth Capital
    10/21/2024$35.00Overweight
    Piper Sandler
    5/17/2024$14.00Outperform
    Oppenheimer
    1/5/2024$8.00Overweight
    Cantor Fitzgerald
    10/26/2022$15.00Buy
    Ladenburg Thalmann
    1/31/2022$14.00 → $18.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CAPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Marban Linda exercised 25,000 shares at a strike of $1.39 and disposed of 12,500 shares, increasing direct ownership by 6% to 211,104 units (SEC Form 4)

    4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

    3/5/25 5:00:13 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF FINANCIAL OFFICER Bergmann Anthony exercised 2,500 shares at a strike of $1.39, increasing direct ownership by 44% to 8,223 units (SEC Form 4)

    4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

    3/4/25 7:00:17 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Litvack Frank exercised 25,000 shares at a strike of $1.39 and covered exercise/tax liability with 2,543 shares, increasing direct ownership by 21% to 129,839 units (SEC Form 4)

    4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

    3/4/25 7:00:13 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on Capricor Therapeutics with a new price target

    Alliance Global Partners initiated coverage of Capricor Therapeutics with a rating of Buy and set a new price target of $20.00

    6/30/25 7:58:51 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Capricor Therapeutics with a new price target

    B. Riley Securities initiated coverage of Capricor Therapeutics with a rating of Buy and set a new price target of $21.00

    6/26/25 8:09:16 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Capricor Therapeutics with a new price target

    Roth Capital initiated coverage of Capricor Therapeutics with a rating of Buy and set a new price target of $31.00

    5/20/25 8:11:35 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAPR
    SEC Filings

    View All

    SEC Form 10-Q filed by Capricor Therapeutics Inc.

    10-Q - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)

    8/11/25 5:25:49 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capricor Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)

    8/11/25 4:06:21 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Capricor Therapeutics Inc.

    SCHEDULE 13G - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)

    7/29/25 11:23:11 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $CAPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Large owner Nippon Shinyaku Co Ltd bought $14,999,998 worth of shares (2,798,507 units at $5.36), increasing direct ownership by 65% to 7,090,351 units (SEC Form 4)

    4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

    9/24/24 4:01:08 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Musket David B bought $1,128 worth of shares (410 units at $2.75), increasing direct ownership by 1% to 31,536 units (SEC Form 4)

    4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

    10/13/23 1:59:57 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collier Earl M Jr bought $28,300 worth of shares (10,000 units at $2.83), increasing direct ownership by 59% to 26,856 units (SEC Form 4)

    4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

    10/12/23 9:15:07 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine

    First-in-human trial of Capricor's StealthX™ vaccine initiated under HHS's Project NextGenTrial conducted and funded by the National Institute of Allergy and Infectious Diseases (NIAID) SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the first subjects have been dosed in a Phase 1 clinical trial evaluating its StealthX™ exosome-based vaccine. The study, funded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) under the U.S. Department of Health and Human Services' Project Nex

    8/18/25 9:00:00 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    Type A meeting with U.S. FDA scheduled to discuss Deramiocel BLA and path toward potential approvalCapricor seeks to resubmit its BLA based on its existing dataset, with HOPE-3 data (expected in Q4 2025) potentially serving as supportive and confirmatory evidence, pending regulatory guidanceAll 483 observations noted in the Pre-License Inspection have been resolved and accepted by the FDAFDA clears IND for StealthX™ exosome-based vaccine; NIAID has initiated the Phase 1 clinical trial Cash balance of approximately $123 million expected to support planned operations into the fourth quarter of 2026 Capricor will host a conference call and webcast today at 4:30 p.m. ET SAN DIEGO, Aug. 1

    8/11/25 4:05:00 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

    SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the regulatory path for its Biologics License Application (BLA) for Deramiocel, the Company's lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). To accommodate this meeting, the Company has rescheduled the release of its financial results for the second quarter ended June 30, 2025, to Monday, August 11, 2025,

    8/8/25 8:30:00 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAPR
    Financials

    Live finance-specific insights

    View All

    Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    Type A meeting with U.S. FDA scheduled to discuss Deramiocel BLA and path toward potential approvalCapricor seeks to resubmit its BLA based on its existing dataset, with HOPE-3 data (expected in Q4 2025) potentially serving as supportive and confirmatory evidence, pending regulatory guidanceAll 483 observations noted in the Pre-License Inspection have been resolved and accepted by the FDAFDA clears IND for StealthX™ exosome-based vaccine; NIAID has initiated the Phase 1 clinical trial Cash balance of approximately $123 million expected to support planned operations into the fourth quarter of 2026 Capricor will host a conference call and webcast today at 4:30 p.m. ET SAN DIEGO, Aug. 1

    8/11/25 4:05:00 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

    SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the regulatory path for its Biologics License Application (BLA) for Deramiocel, the Company's lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). To accommodate this meeting, the Company has rescheduled the release of its financial results for the second quarter ended June 30, 2025, to Monday, August 11, 2025,

    8/8/25 8:30:00 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

    SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the market close on Wednesday, August 13, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on the same day. Title:Capricor Therapeutics Second Quarter 2025 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Wednesday, August 13, 2025Time:4:30 p.m. ETCall Details:Toll-Free: 1-800-717-1738International: 1-646-307-1865Confere

    8/6/25 9:00:00 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Capricor Therapeutics Inc.

    SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)

    11/8/24 9:00:23 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Capricor Therapeutics Inc.

    SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)

    9/24/24 4:03:22 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Capricor Therapeutics Inc.

    SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)

    8/23/24 4:01:31 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAPR
    Leadership Updates

    Live Leadership Updates

    View All

    Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer

    SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced the appointment of Michael Binks, M.D., as Chief Medical Officer, effective immediately. Dr. Binks brings 25 years of experience leading global clinical development and translational research across the pharmaceutical and biotechnology sectors. "Michael is an outstanding addition to Capricor's leadership team as we advance deramiocel toward potential commercialization for the treatment of Duchenne muscular dystrophy (DMD) and explore future pipeline expansion opportunities," said Linda

    5/13/25 9:00:00 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

    SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets today, July 1, 2024. "We are thrilled to be joining the Russell 2000® Index, a testament to our Company's progress across our pipeline marked by significant advancements in our lead program for the treatment of Duchenne muscular dystrophy," said Linda Marbán, Ph.D., Capricor's chief executive officer. "This milestone reflects Ca

    7/1/24 9:00:00 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capricor Therapeutics Appoints Michael Kelliher to Board of Directors

    SAN DIEGO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that the Company has appointed Michael Kelliher to its Board of Directors, effective immediately. Mr. Kelliher, Group Vice President of M&A and Business Development at Horizon Therapeutics, brings to Capricor extensive expertise in business development, strategy, finance and operational leadership across the life sciences industry. "It is a pleasure to welcome Mike to our Board of Directors, who has an extraor

    9/6/23 9:00:00 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care